A cutting-edge mouse study reveals that tirzepatide, the dual GLP-1/GIP drug already hailed for impressive weight loss, does more than trim fat: it slashes the growth of obesity-linked breast tumors. University of Michigan researchers found mice lost about 20 % body weight and adipose tissue while their tumors shrank in tandem, hinting that the blockbuster medication could one day double as a cancer-fighting ally for patients with obesity.
